| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.10. | RenovoRx, Inc.: RenovoRx Advances TAMP into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial | 2 | GlobeNewswire (USA) | ||
| 01.10. | RenovoRx, Inc.: RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer | 2 | GlobeNewswire (USA) | ||
| 14.09. | RenovoRx auf H.C. Wainwright Konferenz: Kommerzieller Erfolg wächst, entscheidende Studiendaten stehen aber noch aus | 4 | Investing.com Deutsch | ||
| RENOVORX Aktie jetzt für 0€ handeln | |||||
| 01.09. | Biotech Stocks At 52-Week Highs - RenovoRx +15%, Evolus, Crinetics Pharmaceuticals, Apogee Therapeutics | 996 | AFX News | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following biotech stocks reached a 52-week high on August 31, 2026, driven by achieving new regulatory milestones or an upcoming acquisition.RenovoRx... ► Artikel lesen | |
| 31.08. | Biotech Stocks At 52-Week Highs - RenovoRx +12%, BlossomHill Therapeutics, Revvity, AtriCure, Biofrontera Inc. | 749 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 28, 2026, as various clinical trials reported initial data and companies reached certain regulatory milestones.RenovoRx... ► Artikel lesen | |
| 25.08. | RenovoRx, Inc.: RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer | 2 | GlobeNewswire (USA) | ||
| 21.08. | RenovoRx regains Nasdaq compliance | 1 | Seeking Alpha | ||
| 21.08. | RenovoRx regains Nasdaq minimum bid price compliance | 1 | Investing.com | ||
| 21.08. | RenovoRx erfüllt wieder NASDAQ-Mindestkursanforderung | 3 | Investing.com Deutsch | ||
| 21.08. | RenovoRx, Inc.: RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | 352 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and... ► Artikel lesen | |
| 20.08. | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.08. | RenovoRx receives U.S. patent allowance for cancer device | 5 | Investing.com | ||
| 20.08. | RenovoRx, Inc.: RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment | 304 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and... ► Artikel lesen | |
| 13.08. | RenovoRx, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 12.08. | RenovoRx, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.08. | RenovoRx, Inc.: RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer | 1.282 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and... ► Artikel lesen | |
| 11.08. | EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027 | 1 | Benzinga.com | ||
| 06.08. | RenovoRx, Inc.: RenovoRx Announces First Commercial Clinical Use of RenovoCath in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors | 323 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and... ► Artikel lesen | |
| 04.08. | RenovoRx, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.06. | RenovoRx, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,45 | +0,31 % | BioNTech SE: BioNTech veröffentlicht am 3. November 2026 Ergebnisse für das dritte Quartal 2026 und informiert über operativen Fortschritt | MAINZ, Deutschland, 20. Oktober 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Dienstag, den 3. November 2026, die Ergebnisse für das dritte Quartal 2026... ► Artikel lesen | |
| MODERNA | 216,50 | -1,07 % | Moderna-Aktie über 240 US$ - wie viel geht noch? | Die Moderna-Aktie setzt ihre spektakuläre Erholung fort und stieg gestern um +6,69% auf 242,08 US$. Damit erreicht der Biotech-Titel den höchsten Stand seit Anfang 2022 und überwindet eine wichtige... ► Artikel lesen | |
| VALNEVA | 2,464 | -0,32 % | Valneva mit SONDERMELDUNG: Diese brandneue Prognose ändert einfach alles - Jetzt handeln, noch vor Börsenschluss! | ||
| AMGEN | 387,80 | -0,60 % | Amgen (AMGN) Sales Grew 10%, but Can Earnings Catch Up to the Price? | ||
| NOVAVAX | 9,710 | -0,92 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| BIOGEN | 213,45 | -0,54 % | BioNTech, Formycon, Biogen - Pharma-Milliarden werden neu verteilt | Die Pharmaindustrie steht vor einer gewaltigen Neuordnung. Während milliardenschwere Blockbuster-Medikamente ihre Patentexklusivität verlieren, drängen günstigere Nachahmer-Präparate auf den Markt.... ► Artikel lesen | |
| ILLUMINA | 253,20 | +0,54 % | Illumina launches three AI genomic analysis tools in early access | ||
| CRISPR THERAPEUTICS | 44,495 | -1,05 % | CRISPR Therapeutics CFO steps down | ||
| PALATIN TECHNOLOGIES | 5,550 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| OCUGEN | 0,719 | -1,10 % | Ocugen, Inc. - 8-K, Current Report | ||
| VIKING THERAPEUTICS | 23,500 | 0,00 % | Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 Years | ||
| INTELLIA THERAPEUTICS | 10,400 | +0,39 % | Intellia Therapeutics-Aktie: Sind 80 US$ möglich? | Die Intellia-Therapeutics-Aktie notiert aktuell bei 12,37 US$ und damit mehr als -90% unter ihrem bisherigen Rekordhoch. Nach dem Ausbruch aus dem langjährigen Abwärtstrend versucht der Biotech-Titel... ► Artikel lesen | |
| TEMPUS AI | 59,04 | -2,14 % | Tempus AI, Inc.: Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC | Study to be presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images
Tempus AI, Inc.... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 0,910 | +0,22 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,076 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report Third Quarter 2026 Financial Results on November 4 |